Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2

Appeal

BDFA : Appeal letter (MSWord 141 KB)

BDFA : Scrutiny letter (MSWord 104 KB)

BDFA : Response to scrutiny letter (MSWord 106 KB)

BDFA : Final scrutiny letter (MSWord 86 KB)

BioMarin : Appeal letter (MSWord 61 KB)

BioMarin : Scrutiny letter (MSWord 88 KB)

BioMarin : Response to scrutiny letter (MSWord 69 KB)

BioMarin : Final scrutiny letter (MSWord 86 KB)

Final draft guidance

Final draft guidance (PDF 309 KB)

Committee papers - FDG (PDF 1.46 MB)

Public committee slides - ACM4 (PDF 1.27 MB)

Draft guidance

Draft consultation document (online commenting)

Draft guidance (downloadable version) (PDF 263 KB)

Committee papers (PDF 26.74 MB)

Equality and health inequalities assessment (downloadable version) (PDF 128 KB)

Public committee slides (PDF 1.7 MB)

Public committee slides (PDF 1.58 MB)

Final scope (PDF 184 KB)

Final stakeholder list (PDF 163 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 258 KB)

Draft scope post referral (PDF 190 KB)

HST12: Final draft guidance (2) (PDF 345 KB)

HST12: Committee papers (FDG2) (PDF 731 KB)

HST12: Public committee slides (FDG2) (PDF 848 KB)

HST12: Managed access agreement (PDF 453 KB)

HST12: Final draft guidance (FDG) (PDF 390 KB)

HST12: Committee papers (FDG) (PDF 7.16 MB)

HST12: Public committee slides (FED) (PDF 1.4 MB)

HST12: Batten Disease Family Association: Appeal letter (PDF 360 KB)

HST12: Batten Disease Family Association: Scrutiny letter (PDF 410 KB)

HST12: Batten Disease Family Association: Response to scrutiny letter (PDF 169 KB)

HST12: Draft guidance document (PDF 508 KB)

HST12: Committee papers (DG) (PDF 31.89 MB)

HST12: Final scope (PDF 229 KB)

HST12: NICE's response to comments on the draft scope and provisional stakeholder list (PDF 366 KB)

HST12: Final stakeholder list (PDF 258 KB)